Khodimatur Rofiah, Susanto Nugroho
OBJECTIVE: Imatinib is a selective BCR-ABL1 kinase inhibitor and a first-line therapy for the treatment of Chronic Myeloid Leukemia (CML). We describe BMP test result of three cases of CML who were diagnosed BCR-ABL positive and treated with imatinib 400mg/day in Pediatric ward Saiful Anwar Hospital, Malang, East Java. CASE: Three cases; case one was a 14-years old male on 8 months treatment, case two was a 13-years old male treated for 6 months, and case three was a 14-years old male treated for one year. The blood smear test showed the level of leukosit and trombosit of the four patients became normal. Myeloblast based on the bone marrow test, case one presented the level of activity decrease to 3%, case two and three presented the decreased of a high level of activity to became normal. CONCLUSION: The duration of follow up of these three patients response showed the efficacy of imatinib. There was a steady decrease in the number of leukosit and trombosit to the normal level of every patient. One patient was in a partial remision CML, two were completed remision.